Completed PHASE1 INTERVENTIONAL 1-arm NCT01834170

EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer

EUS-guided Intratumoral Gemcitabine Therapy in Locally Advanced Unresectable Pancreatic Cancer: A Phase 1 Study

Sponsor: University of Tehran

Interventions Gemcitabine

Updated 7 times since 2017 Last updated: Dec 1, 2014 Started: Apr 30, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pancreatic Adenocarcinoma and is currently completed. University of Tehran leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

In this study, gemcitabine will be injected directly into the tumor by means of endoscopic ultrasound (EUS) in the eligible patients.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Tehran

Data source: University of Tehran

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tehran, Iran